Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm)

Chakkaphan Runcharoen,Phonepadith Xangsayarath,Zahurin Mohamed,Insee Sensorn,Zoe Kordou,Ly Le,Christina Mitropoulou,Sengchanh Kounnavong,Hang Tong,Nareenart Iemwimangsa,Zeina N Al-Mahayri,Myo Thant,Koya Fukunaga,Bassam R Ali,Catherine Lynn T Silao ,Jose B Nevado ,Somphou Sayasone,Sommon Klumsathian,Sharifuddin M Zain ,Dalouny Xayavong,Hilyatuz Zahroh,Sukanya Wattanapokayakit,Ioannis Liopetas,Aumpika Kesornsit,Dzul Azri Mohamed Noor,Evangelia‐Eirini Tsermpini ,Yuh Fen Pung ,Kinasih Prayuni,Tin Maung Hlaing,Surakameth Mahasirimongkol,Nam S Vo ,Maria Koromina,George P Patrinos,Francis Capule ,Angkana Charoenyingwattana,Rika Yuliwulandari,Taisei Mushiroda,Athina Tsikrika,Wasun Chantratita

doi:10.1038/s41439-021-00135-z

Abstract

Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. Next-generation sequencing (NGS) is a cost-effective technology for genotyping several pharmacogenomic loci at once, thereby increasing publicly available data. A panel of 100 pharmacogenes among Southeast Asian (SEA) populations was resequenced using the NGS platform under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Here, we present the frequencies of pharmacogenomic variants and the comparison of these pharmacogenomic variants among different SEA populations and other populations used as controls. We investigated the different types of pharmacogenomic variants, especially those that may have a functional impact. Our results provide substantial genetic variations at 100 pharmacogenomic loci among SEA populations that may contribute to interpopulation variability in drug response phenotypes. Correspondingly, this study provides basic information for further pharmacogenomic investigations in SEA populations.

Highlights

Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events
The 100 PKSeq panel is composed of 37 drug transporter genes, 30 cytochrome P450 (CYP) enzymeencoded genes, 10 uridine diphosphate glucuronosyltransferase (UGT) genes, 5 flavin-containing monooxygenase (FMO) genes, 4 glutathione S-transferase (GST) genes, 4 sulfotransferase (SULT) genes, and others[4]
The results indicated that the Southeast Asian (SEA) populations had modest genetic similarity

Summary

Introduction

Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. The frequencies of pharmacogenomic variants in SEA populations based on the 100 PKSeq panel are reported (Supplementary Tables 1–7). To investigate the proportion of the total pharmacogenomic variants contained in SEA populations, pairwise Fst statistics of the seven SEA countries, UAE, and Greece were performed.

Results

Conclusion